Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities
The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
The antibody was designed and developed at Abzena’s Cambridge, UK,
Expanding US operations to address the increased demand for API development and manufacturing
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
Subscribe To Our Newsletter & Stay Updated